117 related articles for article (PubMed ID: 3658014)
1. [The prognostic significance of alkaline and acid phosphatase levels in the hormonal treatment of patients with prostatic carcinoma].
Mulders PF; Debruyne FM
Ned Tijdschr Geneeskd; 1987 Aug; 131(32):1399-402. PubMed ID: 3658014
[No Abstract] [Full Text] [Related]
2. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
3. The treatment of advanced prostatic carcinoma with medroxyprogesterone.
Rafla S; Johnson R
Curr Ther Res Clin Exp; 1974 Apr; 16(4):261-7. PubMed ID: 4208339
[No Abstract] [Full Text] [Related]
4. Time-dependent prognostic factors in advanced prostatic cancer.
Suciu S; Sylvester RJ; Yamanaka H
Prog Clin Biol Res; 1990; 357():203-15. PubMed ID: 2217465
[No Abstract] [Full Text] [Related]
5. [The acid and alkaline phosphatase activity in the serum of patients with prostatic cancer. The effect of endocrine therapy].
Thijs LG; Poelman JR; Noll WL
Ned Tijdschr Geneeskd; 1969 Jul; 113(30):1303-9. PubMed ID: 5802998
[No Abstract] [Full Text] [Related]
6. New assays for prostatic acid phosphatase and alkaline phosphatase isoenzymes.
Pontes JE
Urology; 1981 Mar; 17(Suppl 3):38-9. PubMed ID: 7010753
[No Abstract] [Full Text] [Related]
7. Prognostic factors of advanced prostatic carcinoma.
Lukkarinen O; Lehikoinen K
Ann Chir Gynaecol Suppl; 1993; 206():9-13. PubMed ID: 8291878
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade].
Regueiro López JC; Ruiz Alvarez Cienfuegos F; Leva Vallejo M; Requena Tapia MJ; Merchan García JA; Prieto Castro R; Alvarez Kindelan J
Actas Urol Esp; 1995 May; 19(5):357-62. PubMed ID: 8659288
[TBL] [Abstract][Full Text] [Related]
9. Clinical aspects of prostatic carcinoma.
Foo KT; Tan EC; Tung KH; Lee YS
Singapore Med J; 1982 Oct; 23(5):269-72. PubMed ID: 7157007
[No Abstract] [Full Text] [Related]
10. [Contribution on the clinical aspects of prostatic carcinoma].
Sladczyk E
Z Arztl Fortbild (Jena); 1967 Jul; 61(13):657-60. PubMed ID: 5598256
[No Abstract] [Full Text] [Related]
11. [Treatment of advanced metastasizing carcinoma of the prostate with estracyt (author's transl)].
Rambausek M; Lutherer S; Terhorst B
Urologe A; 1981 Jul; 20(4):223-7. PubMed ID: 7196632
[TBL] [Abstract][Full Text] [Related]
12. [Enzymological study of prostatic cancer. VI. Serum acid phosphatase level and prognosis of patients with prostatic carcinoma (author's transl)].
Ishibe T
Nihon Hinyokika Gakkai Zasshi; 1974 Feb; 65(2):102-7. PubMed ID: 4471809
[No Abstract] [Full Text] [Related]
13. [Prognosis and treatment of prostatic carcinoma].
Klug W
Zentralbl Chir; 1968 Mar; 93(10):362-6. PubMed ID: 5674208
[No Abstract] [Full Text] [Related]
14. Lung metastases in prostatic carcinoma. Clinical significance.
Varkarakis MJ; Winterberger AR; Gaeta J; Moore RH; Murphy GP
Urology; 1974 Apr; 3(4):447-52. PubMed ID: 4856662
[No Abstract] [Full Text] [Related]
15. [Enzymological study of prostatic cancer. II. Serum lactic dehydrogenase, alkaline phosphatase, leucine aminopeptidase, total acid phosphatase, prostatic acid phosphatase activity and lactic dehydrogenase isoenzymes in prostatic cancer, with special reference to relation with stage and histological malignancy].
Ishibe T; Nihira H; Mori K
Hinyokika Kiyo; 1969 Apr; 15(4):254-65. PubMed ID: 5817349
[No Abstract] [Full Text] [Related]
16. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
17. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
18. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
Kerle D; Williams G; Ware H; Doble A; Allen J; Bloom SR
Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
[TBL] [Abstract][Full Text] [Related]
19. [The diagnostic value of serum acid phosphatases in carcinoma of the prostate (author's transl)].
Braun JS; Habig H; Crüsemann D
Urologe A; 1974 Sep; 13(5):236-41. PubMed ID: 4138057
[No Abstract] [Full Text] [Related]
20. Value of acid phosphatase in screening for carcinoma in patients with prostatism in Nigeria.
Anyanwu SN
East Afr Med J; 1996 Jul; 73(7):457-8. PubMed ID: 8918008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
